Action CYN CLEARMIND MEDICINE INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Clearmind Medicine Inc. Canadian Securities Exchange

Actions

CYN

CA1850534027

Temps Différé Canadian Securities Exchange
Autres places de cotation
 		Varia. 5j. Varia. 1 janv.
- CAD -.--% Graphique intraday de Clearmind Medicine Inc. -13,51% -58,01%
20/06 Clearmind Medicine obtient les droits mondiaux exclusifs sur des composés psychédéliques innovants pour le traitement du SSPT CI
13/06 Clearmind Medicine Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 30 avril 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
Clearmind Medicine Secures Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
Clearmind Medicine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024
Clearmind Medicine : Condensed Interim Consolidated Financial Statements Form 6 K
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Clearmind Applies to Cease Being a Reporting Issuer in Canada
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Clearmind Medicine CEO Issues Letter to Shareholders
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CMND
  4. Action CYN
  5. Actualités Clearmind Medicine Inc.
  6. Autres langues